Kevin Eggan, PhD Archives - CureDuchenne

Title: Group Vice President, Head of Research and Early Development

Organization: BioMarin

Bio: Scientific Luminary and MacArthur Fellowship winner, Kevin Eggan, Ph.D., joined BioMarin as Group Vice President, Head of Research and Early Development in 2020. He is responsible for the execution of BioMarin’s discovery research programs, playing a critical role in shaping the vision of the company’s future research pipeline. Dr. Eggan is charged with further building BioMarin's leadership position in genetic medicines in support of people affected by rare genetic diseases.

2021 FUTURES: Exon Skipping Panel

Information and updates on exon skipping therapies and research from experts in the Duchenne community.

Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

See more from same speaker

Kevin Eggan, PhD

Group Vice President, Head of Research and Early Development

BioMarin

See more from same speaker

Leslie Magnus, MD

Vice President, Medical Affairs

NS Pharma

See more from same speaker

James McArthur, PhD

President and Chief Executive Officer

PepGen

See more from same speaker

Lianna Orlando, PhD

Senior Director of Research

CureDuchenne

See more from same speaker

Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker